Unknown PHASE4 INTERVENTIONAL 3-arm NCT03999125

Anti-VEGF Therapy Versus Dexamethasone Implant for DME

Anti-VEGF Therapy Versus Dexamethasone Implant for Treatment Naive Diabetic Macular Edema: A Randomized Controlled Trial

Sponsor: Sudhalkar Eye Hospital

Conditions Clinically Significant Macular Edema Due to Diabetes Mellitus

Interventions Aflibercept, Ozurdex Drug Implant Product Ranibizumab Injection

Updated 5 times since 2019 Last updated: Jun 25, 2019 Started: Jun 25, 2019 Primary completion: Jun 24, 2021 Completion: Jun 24, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03999125, this PHASE4 trial focuses on Clinically Significant Macular Edema Due to Diabetes Mellitus and remains ongoing. Sponsored by Sudhalkar Eye Hospital, it has been updated 5 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jul 2023 — Jul 2024 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Jul 2023 [monthly]

Not Yet Recruiting PHASE4
Jul 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE4

First recorded

Jun 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sudhalkar Eye Hospital

Data source: Sudhalkar Eye Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bremerhaven, Germany